Caricamento...

The bone marrow microenvironment as a sanctuary for minimal residual disease in CML

Bcr-abl kinase inhibitors have provided proof of principal that targeted therapy holds great promise for the treatment of cancer. However, despite the success of these agents in treating chronic myelogenous leukemia (CML), the majority of patients continue to present with minimal residual disease co...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Nair, Rajesh R., Tolentino, Joel, Hazlehurst, Lori A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2010
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3285111/
https://ncbi.nlm.nih.gov/pubmed/20382130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2010.04.003
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !